Dr. Richard Margolese

Academic title(s): 

Professor of Surgery and Oncology, McGill University

Dr. Richard Margolese
Contact Information
Phone: 
514-340-8222, ext. 23460
Email address: 
richard.margolese [at] mcgill.ca
Biography: 

Professor Margolese has a long career in clinical trials of breast cancer, and has been a leader in the evolution of radical breast surgery to breast conserving surgery. As an organizer and investigator in other trials of hormone and chemotherapy agents as adjuncts to surgery, he has been one of the contributors to significantly improved breast cancer survival rates.

Dr. Margolese is a Professor of Surgical Oncology, is a past president of the National Cancer Institute of Canada and is a member of the Order of Canada in recognition of his career in clinical cancer research.

Location: 
Jewish General Hospital (JGH)
Office: 
E177 (JGH)
Selected publications: 


1: Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL
3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term
Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant
Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 Feb 1;110(2).
doi: 10.1093/jnci/djx162. PubMed PMID: 28954297; PubMed Central PMCID:
PMC5825682.


2: Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A,
Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R,
Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP,
Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to
Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann
Surg Oncol. 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. Epub 2016
Nov 18. PubMed PMID: 27864694; PubMed Central PMCID: PMC5821429.


3: Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA,
Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins
JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal
patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy
(NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016
Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. Epub 2015 Dec 11.
PubMed PMID: 26686960; PubMed Central PMCID: PMC4792658.


4: Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA,
Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins
JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in
situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised,
double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56. doi:
10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11. PubMed PMID: 26686957; PubMed
Central PMCID: PMC4792688.


5: Chapman JA, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE,
Gelmon KA, Wolmark N, Pollak MN. Octreotide LAR and tamoxifen versus tamoxifen in
phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
Breast Cancer Res Treat. 2015 Sep;153(2):353-60. doi: 10.1007/s10549-015-3547-4.
Epub 2015 Aug 15. PubMed PMID: 26276354; PubMed Central PMCID: PMC4681581.


6: Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L,
Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG,
Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG
Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet
Oncol. 2015 Sep;16(9):1037-1048. doi: 10.1016/S1470-2045(15)00041-8. Epub 2015
Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589. PubMed PMID: 26272770;
PubMed Central PMCID: PMC4624323.


7: Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher
L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata
HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib
as a component of neoadjuvant therapy for HER2-positive operable breast cancer
(NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol.
2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4.
PubMed PMID: 24095300.


8: Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L,
Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG,
Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab
added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan
26;366(4):310-20. doi: 10.1056/NEJMoa1111097. PubMed PMID: 22276821; PubMed
Central PMCID: PMC3401076.


9: Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR,
Margolese RG, Swain SM, Costantino JP, Wolmark N. Long-term outcomes of invasive
ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24
randomized clinical trials for DCIS. J Natl Cancer Inst. 2011 Mar
16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11. PubMed PMID:
21398619; PubMed Central PMCID: PMC3107729.


10: Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN,
Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James
J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC,
Wolmark N; National Surgical Adjuvant Breast and Bowel Project. Update of the
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and
Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila).
2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.
PubMed PMID: 20404000; PubMed Central PMCID: PMC2935331.

View more

Clinical Interests: 

Clinical trials of promising new anti-cancer therapies;

Clinical trials in: breast cancer surgery, adjuvant therapy in breast cancer, breast cancer prevention.

Back to top